G
Generation Bio
Engages in developing genetic medicines through gene therapy platform for intrinsic hepatic diseases and systemic diseases
At a glance
- Founded
- 2016
- Headquarters
- Cambridge, United States
- Listing
- IPO 2020
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Series B and later10 investors entered at this stage
- TCTransformation Capital
T. Rowe Price
Casdin Capital- DEDeerfield
Wellington Management
Fidelity Investments- INInvus
Foresite Capital- NHNational Institutes of Health
- FMFarallon Capital Management
Source: Dealroom Talent Intelligence.
Alumni founders
Former Generation Bio employees who went on to found companies, sorted by Dealroom signal score.
DTDyne TherapeuticsEst. 2017
Phillip SamayoaUnited States
UBUmoja BiopharmaEst. 2019
Andy ScharenbergUnited States
CBCarbon BiosciencesEst. 2021
TNTortugas NeuroscienceEst. 2024Global footprint
team presence
across markets
Patents
48 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Generation Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Generation Bio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.